Personalized Assessment of CFTR Allosteric Modulators in Cystic Fibrosis Patients With Rectal Derived Organoids
Event details
| Date | 23.11.2023 |
| Hour | 17:00 › 18:00 |
| Speaker | Nathalie Brandenberg, Ph.D., CEO, Doppl SA & co-CEO, SUN bioscience, Lausanne (CH) |
| Location | |
| Category | Conferences - Seminars |
| Event Language | English |
BIOENGINEERING SEMINAR
Abstract:
Cystic fibrosis (CF) is a genetic disease caused by a bi-allelic mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. When the diagnosis cannot be confirmed by a positive sweat test or/and the identification of two CF-causing variants, international guidelines recommend the use of CFTR functional assavs. These tests assess whether CFTR activity is normal or diminished/absent through measurement of CFTR-mediated chloride secretion/absorption.
Bio:
Positions:
July 2022 - Present Founder, CEO and Board Member, Doppl SA, Lausanne (CH)
Jan 2016 - Present Founder, co-CEO and Board Member, SUN bioscience, Lausanne (CH)
Education:
Aug. 2021-Dec. 2022 Executive MBA, Business Administration and Management, Healthcare Focus, University of Lausanne (CH)
2012-2016 Ph.D., Lutolf Lab, EPFL, Lausanne (CH)
2010-2011 M.Sc. project, The University of Tokyo, Tokyo (JP)
2006-2011 B.Sc. in Life Science & Technology, M.Sc. in Bioengineering, EPFL, Lausanne (CH)
Abstract:
Cystic fibrosis (CF) is a genetic disease caused by a bi-allelic mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. When the diagnosis cannot be confirmed by a positive sweat test or/and the identification of two CF-causing variants, international guidelines recommend the use of CFTR functional assavs. These tests assess whether CFTR activity is normal or diminished/absent through measurement of CFTR-mediated chloride secretion/absorption.
Bio:
Positions:
July 2022 - Present Founder, CEO and Board Member, Doppl SA, Lausanne (CH)
Jan 2016 - Present Founder, co-CEO and Board Member, SUN bioscience, Lausanne (CH)
Education:
Aug. 2021-Dec. 2022 Executive MBA, Business Administration and Management, Healthcare Focus, University of Lausanne (CH)
2012-2016 Ph.D., Lutolf Lab, EPFL, Lausanne (CH)
2010-2011 M.Sc. project, The University of Tokyo, Tokyo (JP)
2006-2011 B.Sc. in Life Science & Technology, M.Sc. in Bioengineering, EPFL, Lausanne (CH)
Practical information
- Informed public
- Free